Compare Credo Technology Group Holding Ltd (CRDO) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs ResMed Inc. — how do they compare? Credo Technology Group Holding Ltd trades at $217.09 (market cap $39.82B), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: Credo Technology Group Holding Ltd is the larger of the two by market cap, and ResMed Inc. pays a 1.16% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and ResMed Inc. for 51 Days on average.
| CRDO | RMD | |
|---|---|---|
Market Cap | $39.82B | $31.89B |
Volume | 9,451,558 | 618,314 |
Sector | Technology | Health |
52-Week High | $302.52 | $277.88 |
52-Week Low | $87.81 | $182.82 |
Typical Hold Time | 22 Days | 51 Days |
Enterprise Value | $39.08B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $220.01, down 0.37% on the day, with strong technical momentum showing bullish moving averages and key support at $213. The company demonstrates exceptional fundamental strength with 114.7% YoY revenue growth and 33.83% net income margins, though valuation metrics remain elevated with a P/E of 74.6. Recent earnings beats and analyst optimism highlight CRDO's position in AI infrastructure connectivity.
Outlook remains positive given triple-digit revenue growth and expanding AI data center demand, but premium valuation and insider selling present near-term risks. Wall Street consensus targets $267.33 with 87.5% buy ratings, though execution risks and customer concentration require monitoring amid rapid expansion.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
